An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray

The global exposure of Sativex(®) (Δ(9)-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was given marketing approval for treating treatment-resistant spasticity in multiple sclerosis (MS). An observational registry to collect safety da...

Full description

Saved in:
Bibliographic Details
Published in:Ther Clin Risk Manag
Main Authors: Etges, Tilden, Karolia, Kari, Grint, Thomas, Taylor, Adam, Lauder, Heather, Daka, Brian, Wright, Stephen
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2016
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5113923/
https://ncbi.nlm.nih.gov/pubmed/27956834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S115014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items